OnKure director amends filing on 15,300-share option

OnKure Therapeutics, Inc. director Isaac Manke filed an amended ownership report reflecting a stock option holding rather than a transaction.

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. director Isaac Manke filed an amended ownership report reflecting a stock option holding rather than a transaction. The amendment states that a previously reported disposition and corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock in connection with an Option Repricing did not occur. The filing instead reports a stock option, exercisable at $18.20 per share, covering 15,300 underlying shares and expiring on October 3, 2034. According to the vesting schedule, 1/36 of the option vested on November 4, 2024 and 1/36 continues to vest monthly, contingent on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Manke Isaac

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy) F1, F2	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 15,300 contracts (Direct)

Footnotes (2)

1. F1. The original Form 4, filed August 11, 2026, reported the disposition on August 7, 2026 of an option to purchase 15,300 shares of Class A Common Stock (the "Disposition"), and a corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock (the "Acquisition"), each in connection with an Option Repricing, as defined in footnote 3 of the original Form 4. The Disposition and Acquisition did not occur.
2. F2. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

Underlying shares: 15,300 shares Exercise price: $18.20 per share Option expiration: October 3, 2034 +1 more

4 metrics

Underlying shares 15,300 shares Shares of Class A Common Stock subject to the reported stock option holding

Exercise price $18.20 per share Exercise price of the stock option reported as a holding

Option expiration October 3, 2034 Expiration date of the stock option on Class A Common Stock

Vesting start date November 4, 2024 Date when 1/36 of the shares subject to the option initially vested

Key Terms

Option Repricing, Class A Common Stock, vesting

3 terms

Option Repricing financial

"each in connection with an Option Repricing, as defined in footnote 3"

Class A Common Stock financial

"option to purchase 15,300 shares of Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vesting financial

"1/36th of the shares subject to the option vested on November 4, 2024"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 4/A filed for OKUR by Isaac Manke change?

The amendment clarifies that a previously reported disposition and acquisition of an option to purchase 15,300 shares of Class A Common Stock in connection with an Option Repricing did not occur. Instead, it reflects a continuing stock option holding with defined exercise and vesting terms.

How many OKUR shares are covered by Isaac Manke’s option in this Form 4/A?

The stock option reported covers 15,300 underlying shares of OnKure Therapeutics Class A Common Stock. This figure represents the number of shares that may be purchased upon exercise of the option, subject to the vesting schedule and continued service conditions described in the filing.

What is the exercise price and expiration date of Isaac Manke’s OKUR stock option?

The option has an exercise price of $18.20 per share and an expiration date of October 3, 2034. These terms define the cost to purchase each underlying share and the final date by which the option may be exercised, assuming vesting and service conditions are met.

How does Isaac Manke’s OKUR option vest according to the amended filing?

The filing states that 1/36 of the shares subject to the option vested on November 4, 2024, with an additional 1/36 vesting each month thereafter. Vesting continues only while the reporting person remains a service provider through each applicable vesting date.

Was Isaac Manke’s OKUR Form 4/A filed under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is not marked as affirmatively relying on a trading plan. Combined with the absence of any plan-related disclosure in the footnotes, this indicates the holding information is not reported as being under a pre-arranged Rule 10b5-1 plan.

Does this OKUR Form 4/A report any actual buy or sell transactions by Isaac Manke?

No buy or sell transactions are reported. The amendment explains that the previously reported Disposition and Acquisition of an option did not occur. The entry functions as a holding record for the stock option, showing its current terms and remaining underlying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2026 - 04:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/11/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$18.2							(2)	10/03/2034	Class A Common Stock	15,300		15,300	D

Explanation of Responses:

1. The original Form 4, filed August 11, 2026, reported the disposition on August 7, 2026 of an option to purchase 15,300 shares of Class A Common Stock (the "Disposition"), and a corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock (the "Acquisition"), each in connection with an Option Repricing, as defined in footnote 3 of the original Form 4. The Disposition and Acquisition did not occur.

2. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

	/s/ Rogan Nunn, by power of attorney	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)